Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

Posted: Thursday, June 22, 2017

Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy plus trastuzumab plus placebo vs chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.